Immunitybio provides regulatory update on global submission for anktiva + bcg in bcg unresponsive non-muscle invasive bladder cancer with carcinoma in situ in europe and united kingdom

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx) today announced the completion of the submissions of its marketing authorization applications (maa) for anktiva® (nogapendekin alfa inbakicept) plus bacillus calmette-guÉrin (bcg) for the treatment of adult patients with bcg-unresponsive non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), with or without papillary tumors, to both the european union (eu) european medicines agency (ema) and the united king.
IBRX Ratings Summary
IBRX Quant Ranking